Armata Pharmaceuticals, Inc. (ARMP) Misses Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ARMP Hot Sheet
Join SI Premium – FREE
Armata Pharmaceuticals, Inc. (NYSE: ARMP) reported Q3 EPS of ($0.74), $0.24 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $0 versus the consensus estimate of $1.38 million.
For earnings history and earnings-related data on Armata Pharmaceuticals, Inc. (ARMP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arch Capital (ACGL) PT Raised to $106 at Keefe, Bruyette & Woods
- Eaton (ETN) spreader of 2248 contracts November 6 weekly 397.50 and 420 calls as share price up 7.1%
- U.S. officials held up approval for American chipmaking equipment needed by SK Hynix to expand China production - Reuters
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
